MeSH term
Frequency | Condition_Probility | Adult | 10 | 0.0 |
Aged | 8 | 0.0 |
Female | 16 | 0.0 |
Humans | 45 | 0.0 |
Male | 15 | 0.0 |
Middle Aged | 11 | 0.0 |
Animals | 22 | 0.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 23 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Prognosis | 5 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Mutation | 3 | 0.0 |
Comparative Study | 9 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Base Sequence | 12 | 0.0 |
Cell Line | 10 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
In Vitro | 3 | 0.0 |
Mice | 11 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Rabbits | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Virulence/genetics | 2 | 2.0 |
Binding Sites | 5 | 0.0 |
Cells, Cultured | 5 | 0.0 |
Fibroblasts | 2 | 0.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 11 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Enzyme Induction | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Receptor, TIE-2 | 2 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Transfection | 3 | 0.0 |
Receptors, TIE | 5 | 16.0 |
Carcinoma, Hepatocellular/*therapy | 2 | 8.0 |
*Embolization, Therapeutic | 3 | 13.0 |
English Abstract | 8 | 0.0 |
Fibrinogen/administration & dosage | 2 | 100.0 |
Hepatic Artery | 3 | 5.0 |
*Immunotherapy | 3 | 1.0 |
Iodized Oil/administration & dosage | 3 | 18.0 |
Liver Neoplasms/*therapy | 2 | 8.0 |
Picibanil/*administration & dosage | 6 | 42.0 |
Thrombin/administration & dosage | 3 | 75.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Stromelysin 1 | 4 | 10.0 |
Transforming Growth Factor beta/*pharmacology | 4 | 1.0 |
Molecular Sequence Data | 12 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Child | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Protein-Tyrosine Kinase/*genetics | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
*Chemoembolization, Therapeutic | 2 | 8.0 |
Fibrinogen/*administration & dosage | 4 | 57.0 |
Administration, Oral | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Rats | 4 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Metalloendopeptidases/*genetics | 2 | 2.0 |
Plasmids | 2 | 0.0 |
Japan | 2 | 0.0 |
